In conclusion, our studies demonstrate that NLRP6 potentiates PI3K/AKT pathway by promoting p85α degradation via selective autophagy and that targeting the NLRP6/p85α interaction might serve as a promising therapeutic strategy to inhibit PI3K/AKT pathway against tumour in future (Fig. 6n). The gene discussed is AKT1; the disease is neoplasm.